NSABP study confirms oncotype DX predicts chemotherapy benefit in breast cancer patients
Oncology 20(7): 789-790
2006
ISSN/ISBN: 0890-9091 PMID: 16841801 Document Number: 602351
Document emailed within 1 workday
Related Documents
Panousis, D.; Ntasiou, P.; Grosomanidis, D.; Chatzopoulos, K.; Paraskevakou, G.; Kontogianni, P.; Charitidou, E.; Xepapadakis, G. 2017: Impact of Oncotype DX on chemotherapy assignment: a retrospective single-center study on female breast cancer patients Journal of BUON: Official Journal of the Balkan Union of Oncology 22(5): 1199-1208Fetting, J.H.; Siminoff, L.A.; Piantadosi, S.; Abeloff, M.D.; Damron, D.J.; Sarsfield, A.M. 1990: Effect of patients' expectations of benefit with standard breast cancer adjuvant chemotherapy on participation in a randomized clinical trial: a clinical vignette study Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 8(9): 1476-1482
Marshall, E. 1995: Breast cancer. Reanalysis confirms results of 'tainted' study Science 270(5242): 1562
Mamounas, E.P.; Budd, G.Thomas.; Miller, K.D. 2008: Incorporating the Oncotype DX breast cancer assay into community practice: an expert Q&A and case study sampling Clinical Advances in Hematology and Oncology: H&o 6(2 Suppl. 3): 1-8
Mamounas, E.; Budd, G.Thomas.; Miller, K. 2008: Incorporating the Oncotype DX breast cancer assay into community practice: An expert Q & A and case study sampling Clinical Advances in Hematology and Oncology: H&o 6(2): S1-S8
Brightwell, R.; Eng, K.; Lele, S. 2017: Use of hematologic biomarkers during chemotherapy predicts survival in ovarian cancer patients European Journal of Gynaecological Oncology 38(3): 378-381
Fietkau, R.; Rödel, C. 2000: Postoperative radiochemotherapy of rectal carcinoma reduces the incidence of locoregional recurrences but does not improve the prognosis of patients--the results of a randomized study of the NSABP-R02. National Surgical Adjuvant Breast and Bowel Project Protocol Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 176(8): 381-382
Harbeck, N.; Kates, R.E.; Look, M.P.; Meijer-Van Gelder, M.E.; Klijn, J.G.M.; Krüger, A.; Kiechle, M.; Jänicke, F.; Schmitt, M.; Foekens, J.A. 2002: Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424) Cancer Research 62(16): 4617-4622
Liu, Z.; Han, X.; Tian, C.; Chen, J.; Lei, L.; Liang, Q.; Lv, X.; Tang, S.; Ning, P. 2018: A study on the relationship between chemotherapy-induced cognitive impairment and age in patients with breast cancer Journal of BUON: Official Journal of the Balkan Union of Oncology 23(6): 1601-1605
Marzian, O. 2007: Treatment of acute bronchitis in children and adolescents. Non-interventional postmarketing surveillance study confirms the benefit and safety of a syrup made of extracts from thyme and ivy leaves MMW Fortschritte der Medizin 149(27-28 (Suppl): 69-74
Stamatovic, L.; Susnjar, S.; Gavrilovic, D.; Minic, I.; Ursulovic, T.; Dzodic, R. 2018: The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients Journal of Buon: Official Journal of the Balkan Union of Oncology 23(5): 1273-1280
2006: Comparative effects of the administration period of adjuvant chemotherapy using doxifluridine (5'-DFUR) for 1 year versus 3 years after breast cancer surgery by the Shimane Breast Cancer Study Group Anticancer Research 26(1b): 591-597
Nichols, W.C.; Kvols, L.K.; Ingle, J.N.; Edmonson, J.H.; Ahmann, D.L.; Rubin, J.; O'Connell, M.J. 1978: Phase Ii study of triazinate and pyrazofurin in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy Cancer Treatment Reports 62(5): 837-839
Bowles, D.W.; Rabinovitch, R.; Borges, V.; Urquhart, A.; Singh, M.; Finlayson, C.; Elias, A. 2007: A young woman with a small ER-positive breast cancer, a micrometastatic axillary lymph node, and an intermediate oncotype DX recurrence score Oncology 21(10): 1212-1217
Maeda, T.; Takahashi, T.; Kojima, O. 1986: Study of local chemotherapy of regional lymph nodes in patients with breast cancer using activated carbon adsorbing adriamycin Nihon Geka Gakkai Zasshi 87(4): 470
Jiang, Z.F.; Xu, F.R.; Fan, J.; Li, B.J.; Gao, J.N.; Hu, J.W.; Wang, X.J.; Zhang, Y.Q.; Wang, J.H.; Li, F.; Liu, Q.; Liu, Y.H.; Wang, S.; Wang, Y.S.; Ouyang, Q.C.; Hu, B.; Sun, G.P.; Zhang, Y.; Zang, A.M.; Fan, P.Z.; Wu, C.P.; Liu, J.; Zhang, H.W.; Wang, W.; Hu, X.C.; Tang, L.L.; Zhang, J.; Bao, Y.Y.; Geng, C.Z.; Sun, Q.; Zhang, F.; Yin, Y.M.; Jiang, H.C.; An, Y.H. 2018: A multicenter, randomized, controlled, phase Ⅳ clinical study of PEG-rhG-CSF for preventing chemotherapy induced neutropenia in patients with breast cancer Zhonghua Yi Xue Za Zhi 98(16): 1231-1235
He, Q.; Fornander, T.; Johansson, H.; Johansson, U.; Hu, G.Z.; Rutqvist, L.-E.; Skog, S. 2006: Thymidine kinase 1 in serum predicts increased risk of distant or loco-regional recurrence following surgery in patients with early breast cancer Anticancer Research 26(6c): 4753-4759
Gerson Cwilich, R.; Alban de la Torre, L.F.; Villalobos Prieto, A.; Serrano Olvera, J.A. 2012: Clinicopathological features, prognosis and influence in the adjuvant treatment of the risk recurrence groups determined by the 21 gene expression profile, Oncotype Dx®, in early breast cancer Gaceta Medica de Mexico 148(2): 117-124
Liang, X.-f.; Ma, D.-c.; Ding, Z.-y.; Liu, Z.-z.; Guo, F.; Liu, L.; Yu, H.-y.; Han, Y.-l.; Xie, X.-d. 2013: Autologous cytokine-induced killer cells therapy on the quality of life of patients with breast cancer after adjuvant chemotherapy: a prospective study Zhonghua Zhong Liu Za Zhi 35(10): 764-768
Halim, A.; Wahba, H. 2012: Cisplatin-ifosfamide combination chemotherapy in metastatic triple-negative, anthracycline- and taxane-pretreated breast cancer patients; a phase II study Journal of BUON: Official Journal of the Balkan Union of Oncology 17(2): 254-258